Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
